|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
GB1458148A
(en)
*
|
1974-04-19 |
1976-12-08 |
Wyeth John & Brother Ltd |
Carbocyclic-fused ring quinoline derivatives
|
|
JPS57123267A
(en)
|
1981-01-23 |
1982-07-31 |
Kansai Paint Co Ltd |
Thermosetting paint composition
|
|
SE8103843L
(sv)
|
1981-06-18 |
1982-12-19 |
Astra Laekemedel Ab |
Farmaceutisk mixtur
|
|
JPS59101423A
(ja)
|
1982-12-02 |
1984-06-12 |
Takada Seiyaku Kk |
新規なニフエジピン固形製剤
|
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
|
EP0154434B1
(en)
|
1984-02-17 |
1993-01-27 |
Genentech, Inc. |
Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods
|
|
US4582789A
(en)
|
1984-03-21 |
1986-04-15 |
Cetus Corporation |
Process for labeling nucleic acids using psoralen derivatives
|
|
DE8411409U1
(de)
|
1984-04-11 |
1984-08-30 |
Dr.-Ing. Walter Frohn-Betriebe, 8000 München |
Entgasungsventil fuer lager- und/oder transportbehaelter
|
|
US4563417A
(en)
|
1984-08-31 |
1986-01-07 |
Miles Laboratories, Inc. |
Nucleic acid hybridization assay employing antibodies to intercalation complexes
|
|
EP0183858B1
(de)
|
1984-11-22 |
1988-09-14 |
Holsten-Brauerei AG |
Bier und Verfahren zu dessen Herstellung
|
|
CA1264738A
(en)
|
1984-12-04 |
1990-01-23 |
Eli Lilly And Company |
Treatment of tumors in mammals
|
|
JPS62168137A
(ja)
|
1985-12-20 |
1987-07-24 |
Fuji Photo Film Co Ltd |
ハロゲン化銀カラ−写真感光材料およびその処理方法
|
|
JPH07106295B2
(ja)
|
1986-07-22 |
1995-11-15 |
エーザイ株式会社 |
調湿剤
|
|
US4743450A
(en)
|
1987-02-24 |
1988-05-10 |
Warner-Lambert Company |
Stabilized compositions
|
|
CA1339136C
(en)
|
1987-07-01 |
1997-07-29 |
Sailesh Amilal Varia |
Amorphous form of aztreonam
|
|
US5009894A
(en)
*
|
1988-03-07 |
1991-04-23 |
Baker Cummins Pharmaceuticals, Inc. |
Arrangement for and method of administering a pharmaceutical preparation
|
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US4983615A
(en)
|
1989-06-28 |
1991-01-08 |
Hoechst-Roussel Pharmaceuticals Inc. |
Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
|
|
US5180818A
(en)
|
1990-03-21 |
1993-01-19 |
The University Of Colorado Foundation, Inc. |
Site specific cleavage of single-stranded dna
|
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
|
EP0834575B1
(en)
|
1990-12-06 |
2001-11-28 |
Affymetrix, Inc. (a Delaware Corporation) |
Identification of nucleic acids in samples
|
|
GB9105677D0
(en)
|
1991-03-19 |
1991-05-01 |
Ici Plc |
Heterocyclic compounds
|
|
US5367057A
(en)
|
1991-04-02 |
1994-11-22 |
The Trustees Of Princeton University |
Tyrosine kinase receptor flk-2 and fragments thereof
|
|
US5721237A
(en)
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
|
EP0584222B1
(en)
|
1991-05-10 |
1997-10-08 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
JPH04341454A
(ja)
|
1991-05-16 |
1992-11-27 |
Canon Inc |
シート収納装置
|
|
US5750376A
(en)
|
1991-07-08 |
1998-05-12 |
Neurospheres Holdings Ltd. |
In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
|
|
JPH05194259A
(ja)
|
1991-08-30 |
1993-08-03 |
Mitsubishi Kasei Corp |
抗消化性潰瘍剤
|
|
EP0648264A4
(en)
|
1992-06-03 |
1997-10-01 |
Univ Case Western Reserve |
BANDAGE ALLOWING THE CONTINUOUS APPLICATION OF ORGANIC PRODUCTS.
|
|
TW271400B
(es)
|
1992-07-30 |
1996-03-01 |
Pfizer |
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
JPH06153952A
(ja)
|
1992-11-26 |
1994-06-03 |
Nobuaki Tamamaki |
微量未知二重鎖ｄｎａ分子の増幅、標識を行うための前処理方法
|
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
|
DE69324504T2
(de)
|
1993-01-19 |
1999-08-26 |
Warner-Lambert Co. |
Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
|
|
US6027880A
(en)
|
1995-08-02 |
2000-02-22 |
Affymetrix, Inc. |
Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
|
|
JPH07176103A
(ja)
|
1993-12-20 |
1995-07-14 |
Canon Inc |
光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体
|
|
GB9326136D0
(en)
|
1993-12-22 |
1994-02-23 |
Erba Carlo Spa |
Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
JP3660391B2
(ja)
|
1994-05-27 |
2005-06-15 |
株式会社東芝 |
半導体装置の製造方法
|
|
JPH0848078A
(ja)
|
1994-08-05 |
1996-02-20 |
Nippon Paper Ind Co Ltd |
感熱記録体
|
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
|
US5656454A
(en)
|
1994-10-04 |
1997-08-12 |
President And Fellows Of Harvard College |
Endothelial cell-specific enhancer
|
|
IL115256A0
(en)
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
|
JPH08176138A
(ja)
|
1994-12-19 |
1996-07-09 |
Mercian Corp |
イソクマリン誘導体
|
|
US5948438A
(en)
|
1995-01-09 |
1999-09-07 |
Edward Mendell Co., Inc. |
Pharmaceutical formulations having improved disintegration and/or absorptivity
|
|
US5658374A
(en)
|
1995-02-28 |
1997-08-19 |
Buckman Laboratories International, Inc. |
Aqueous lecithin-based release aids and methods of using the same
|
|
US5624937A
(en)
|
1995-03-02 |
1997-04-29 |
Eli Lilly And Company |
Chemical compounds as inhibitors of amyloid beta protein production
|
|
EP2295415A1
(en)
|
1995-03-30 |
2011-03-16 |
OSI Pharmaceuticals, Inc. |
Quinazoline derivatives
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
DK0831829T3
(da)
|
1995-06-07 |
2003-12-15 |
Pfizer |
Heterocykliske, ringkondenserede pyrimidinderivater
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
JPH0923885A
(ja)
|
1995-07-12 |
1997-01-28 |
Dai Ichi Seiyaku Co Ltd |
遺伝子発現ライブラリー及びその製造法
|
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
|
US6346398B1
(en)
|
1995-10-26 |
2002-02-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
|
|
US6143764A
(en)
|
1995-11-07 |
2000-11-07 |
Kirin Beer Kabushiki Kaisha |
Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
|
|
US5849759A
(en)
|
1995-12-08 |
1998-12-15 |
Berlex Laboratories, Inc. |
Naphthyl-substituted benzimidazole derivatives as anti-coagulants
|
|
GB9604361D0
(en)
|
1996-02-29 |
1996-05-01 |
Pharmacia Spa |
4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
|
|
JPH09234074A
(ja)
|
1996-03-04 |
1997-09-09 |
Sumitomo Electric Ind Ltd |
アダプター二本鎖ｄｎａ及びそれを用いたｄｎａ増幅方法
|
|
AU2733997A
(en)
|
1996-04-17 |
1997-11-07 |
Du Pont Pharmaceuticals Company |
N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
|
|
US6057100A
(en)
|
1996-06-07 |
2000-05-02 |
Eos Biotechnology, Inc. |
Oligonucleotide arrays
|
|
WO1998000134A1
(en)
|
1996-06-28 |
1998-01-08 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
EP0912559B1
(en)
|
1996-07-13 |
2002-11-06 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
BR9710362A
(pt)
|
1996-07-13 |
1999-08-17 |
Glaxo Group Ltd |
Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
|
|
IL128994A
(en)
|
1996-09-25 |
2004-12-15 |
Zeneca Ltd |
History of quinoline and naphthyridine and their salts, processes for their preparation, pharmaceutical preparations containing them and their use as medicines
|
|
DE69722019T2
(de)
|
1996-09-30 |
2003-11-27 |
Nihon Nohyaku Co., Ltd. |
1,2,3-thiadiazol-derivate und ihre salze, mittel zur kontrolle von krankheiten in landwirtschaft und gartenbau und eine methode zu ihrer anwendung
|
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
CN1237177A
(zh)
|
1996-11-27 |
1999-12-01 |
辉瑞大药厂 |
稠合的二环嘧啶衍生物
|
|
AU6248798A
(en)
|
1997-01-29 |
1998-08-18 |
Eli Lilly And Company |
Treatment for premenstrual dysphoric disorder
|
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
|
WO1998037079A1
(en)
|
1997-02-19 |
1998-08-27 |
Berlex Laboratories, Inc. |
N-heterocyclic derivatives as nos inhibitors
|
|
US6090556A
(en)
|
1997-04-07 |
2000-07-18 |
Japan Science & Technology Corporation |
Method for quantitatively determining the expression of a gene
|
|
AU7526798A
(en)
|
1997-04-18 |
1998-11-27 |
Smithkline Beecham Plc |
Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
|
|
EP1019040B1
(en)
|
1997-05-23 |
2004-09-29 |
Bayer Corporation |
Aryl ureas for the treatment of inflammatory or immunomodulatory diseases
|
|
KR100543614B1
(ko)
|
1997-06-10 |
2006-01-20 |
신톤 비.브이. |
4-페닐피페리딘 화합물
|
|
US6093742A
(en)
|
1997-06-27 |
2000-07-25 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of p38
|
|
AU8283898A
(en)
|
1997-06-30 |
1999-01-25 |
University Of Maryland At Baltimore |
Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
|
|
HUP0002236A3
(en)
|
1997-07-01 |
2003-12-29 |
Pfizer Prod Inc |
Solubilized sertraline compositions and process for their preparation
|
|
BE1011251A3
(fr)
|
1997-07-03 |
1999-06-01 |
Ucb Sa |
Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
|
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
|
JP3765918B2
(ja)
|
1997-11-10 |
2006-04-12 |
パイオニア株式会社 |
発光ディスプレイ及びその駆動方法
|
|
JP4194678B2
(ja)
|
1997-11-28 |
2008-12-10 |
キリンファーマ株式会社 |
キノリン誘導体およびそれを含む医薬組成物
|
|
JP2001526222A
(ja)
|
1997-12-22 |
2001-12-18 |
バイエル コーポレイション |
アリールおよびヘテロアリール置換複素環尿素を使用するｐ３８キナーゼ活性の阻害
|
|
AU2198999A
(en)
|
1997-12-22 |
1999-07-12 |
Bayer Corporation |
Inhibition of raf kinase using substituted heterocyclic ureas
|
|
NZ505843A
(en)
|
1997-12-22 |
2003-06-30 |
Bayer Ag |
Diphenyl ureas compounds for treating cancer and raf kinase related diseases
|
|
JP4403482B2
(ja)
|
1997-12-22 |
2010-01-27 |
バイエル コーポレイション |
置換複素環尿素合成のための中間体およびその製造方法
|
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
CN1310706A
(zh)
|
1998-02-25 |
2001-08-29 |
遗传研究所有限公司 |
磷脂酶抑制剂
|
|
JPH11322596A
(ja)
|
1998-05-12 |
1999-11-24 |
Shionogi & Co Ltd |
白金錯体および環状リン酸エステルアミドを含有する抗癌剤
|
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
|
US8097648B2
(en)
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
AU762998B2
(en)
|
1998-06-17 |
2003-07-10 |
Eisai R&D Management Co., Ltd. |
Macrocyclic analogs and methods of their use and preparation
|
|
US6653341B1
(en)
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
EA003786B1
(ru)
|
1998-11-19 |
2003-10-30 |
Варнер Ламберт Компани |
N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
|
|
TWI230618B
(en)
|
1998-12-15 |
2005-04-11 |
Gilead Sciences Inc |
Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
|
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
ES2208261T3
(es)
|
1999-01-22 |
2004-06-16 |
Kirin Beer Kabushiki Kaisha |
Derivados de quinolina y derivados de quinazolina.
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
PL205557B1
(pl)
|
1999-02-10 |
2010-05-31 |
Astrazeneca Ab |
Pochodne indolu
|
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
|
JP2000328080A
(ja)
|
1999-03-12 |
2000-11-28 |
Shin Etsu Chem Co Ltd |
シートベルト用低摩擦化処理剤
|
|
RS49836B
(sr)
|
1999-03-31 |
2008-08-07 |
Pfizer Products Inc., |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
|
US6887468B1
(en)
|
1999-04-28 |
2005-05-03 |
Board Of Regents, The University Of Texas System |
Antibody kits for selectively inhibiting VEGF
|
|
AU4778500A
(en)
|
1999-05-20 |
2000-12-12 |
Takeda Chemical Industries Ltd. |
Composition containing ascorbic acid salt
|
|
JP4304357B2
(ja)
|
1999-05-24 |
2009-07-29 |
独立行政法人理化学研究所 |
完全長ｃＤＮＡライブラリーの作成法
|
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
WO2001012600A1
(en)
|
1999-08-12 |
2001-02-22 |
Cor Therapeutics, Inc. |
INHIBITORS OF FACTOR Xa
|
|
AR025752A1
(es)
|
1999-09-28 |
2002-12-11 |
Bayer Corp |
Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
|
|
UA75054C2
(uk)
|
1999-10-13 |
2006-03-15 |
Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг |
Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
|
|
JP2001131071A
(ja)
|
1999-10-29 |
2001-05-15 |
Meiji Seika Kaisha Ltd |
非晶質および非晶質を含有する医薬組成物
|
|
WO2001032926A2
(en)
|
1999-11-01 |
2001-05-10 |
Curagen Corporation |
Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
|
|
WO2001036403A1
(en)
|
1999-11-16 |
2001-05-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Urea derivatives as anti-inflammatory agents
|
|
UA75055C2
(uk)
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
|
EP1255536B1
(en)
|
1999-12-22 |
2006-06-28 |
Sugen, Inc. |
Indolinone derivatives for modulation of c-kit tyrosine protein kinase
|
|
WO2001047890A1
(en)
|
1999-12-24 |
2001-07-05 |
Kirin Beer Kabushiki Kaisha |
Quinoline and quinazoline derivatives and drugs containing the same
|
|
ES2238335T3
(es)
|
1999-12-24 |
2005-09-01 |
Kyowa Hakko Kogyo Co., Ltd. |
Derivados de purina condensados.
|
|
MY130363A
(en)
|
2000-02-15 |
2007-06-29 |
Sugen Inc |
"pyrrole substituted 2-indolinone protein kinase inhibitors"
|
|
JP3657203B2
(ja)
|
2000-04-21 |
2005-06-08 |
エーザイ株式会社 |
銅クロロフィリン塩含有液剤組成物
|
|
EP1287029A2
(en)
|
2000-06-09 |
2003-03-05 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of colon cancer
|
|
AU2001277621A1
(en)
|
2000-08-09 |
2002-03-04 |
Astrazeneca Ab |
Antiangiogenic bicyclic derivatives
|
|
ATE419239T1
(de)
*
|
2000-10-20 |
2009-01-15 |
Eisai R&D Man Co Ltd |
Verfahren zur herstellung von 4-phenoxy chinolin derivaten
|
|
TWI283575B
(en)
|
2000-10-31 |
2007-07-11 |
Eisai Co Ltd |
Medicinal compositions for concomitant use as anticancer agent
|
|
WO2002041882A2
(en)
|
2000-11-22 |
2002-05-30 |
Novartis Ag |
Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
|
|
JP2004517080A
(ja)
|
2000-11-29 |
2004-06-10 |
グラクソ グループ リミテッド |
Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
|
|
US7101663B2
(en)
|
2001-03-02 |
2006-09-05 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
PCR method
|
|
EP1490362A2
(en)
|
2001-03-08 |
2004-12-29 |
Millennium Pharmaceuticals, Inc. |
(homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases
|
|
ATE406892T1
(de)
|
2001-04-06 |
2008-09-15 |
Wyeth Corp |
Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
|
|
US20040171068A1
(en)
|
2001-04-19 |
2004-09-02 |
Juergen Wehland |
Method for producing stable, regeneratable antibody arrays
|
|
JP3602513B2
(ja)
|
2001-04-27 |
2004-12-15 |
麒麟麦酒株式会社 |
アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
|
|
ES2256466T3
(es)
|
2001-04-27 |
2006-07-16 |
Kirin Beer Kabushiki Kaisha |
Derivado de quinolina que tienen grupo azolilo y derivados de quinazolina.
|
|
JP2003026576A
(ja)
|
2001-05-09 |
2003-01-29 |
Eisai Co Ltd |
味覚改善製剤
|
|
US6812341B1
(en)
|
2001-05-11 |
2004-11-02 |
Ambion, Inc. |
High efficiency mRNA isolation methods and compositions
|
|
MXPA03010401A
(es)
|
2001-05-16 |
2004-03-09 |
Novartis Ag |
Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico.
|
|
CA2454538A1
(en)
|
2001-06-22 |
2003-01-03 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
|
|
GB0117144D0
(en)
|
2001-07-13 |
2001-09-05 |
Glaxo Group Ltd |
Process
|
|
US20030013208A1
(en)
|
2001-07-13 |
2003-01-16 |
Milagen, Inc. |
Information enhanced antibody arrays
|
|
JP4824213B2
(ja)
|
2001-07-16 |
2011-11-30 |
日本メナード化粧品株式会社 |
キトサン含有錠剤
|
|
GB0119467D0
(en)
|
2001-08-09 |
2001-10-03 |
Smithkline Beecham Plc |
Novel compound
|
|
AU2002341621A1
(en)
|
2001-09-10 |
2003-03-24 |
Meso Scale Technologies, Llc |
Methods, reagents, kits and apparatus for protein function analysis
|
|
EP1427379B1
(en)
|
2001-09-20 |
2008-08-13 |
AB Science |
Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
|
|
EP1432422A2
(en)
|
2001-09-27 |
2004-06-30 |
Novartis AG |
Use of c-kit inhibitors for the treatment of myeloma
|
|
JP2005508336A
(ja)
|
2001-09-27 |
2005-03-31 |
アラーガン、インコーポレイテッド |
キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類
|
|
EP1435959A2
(en)
|
2001-10-09 |
2004-07-14 |
University of Cincinnati |
Inhibitors of the egf receptor for the treatment of thyroid cancer
|
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
EP1447405A4
(en)
|
2001-10-17 |
2005-01-12 |
Kirin Brewery |
CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
|
|
AU2002359489B2
(en)
|
2001-11-27 |
2008-10-30 |
Wyeth Holdings Corporation |
3-cyanoquinolines as inhibitors of EGF-R and Her2 kinases
|
|
GB0201508D0
(en)
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
|
JP4542783B2
(ja)
|
2002-03-05 |
2010-09-15 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤
|
|
BR0308343A
(pt)
|
2002-03-12 |
2006-06-06 |
Bristol Myers Squibb Co |
composições farmacêuticas na forma de pó, método para preparar uma suspensão oral de uma droga, método para mascarar o sabor amargo ou outro sabor de uma droga e suspensão oral de des-quinolona
|
|
AU2003226676A1
(en)
|
2002-03-20 |
2003-09-29 |
Dana-Farber Cancer Institute Inc. |
Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
|
|
US7598258B2
(en)
|
2002-05-01 |
2009-10-06 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
WO2004006862A2
(en)
|
2002-07-16 |
2004-01-22 |
Children's Medical Center Corporation |
A method for the modulation of angiogenesis
|
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
|
US7252976B2
(en)
|
2002-08-28 |
2007-08-07 |
Board Of Regents The University Of Texas System |
Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
|
|
CN100339376C
(zh)
|
2002-08-30 |
2007-09-26 |
卫材R&D管理有限公司 |
含氮芳环衍生物
|
|
RU2005114018A
(ru)
|
2002-10-09 |
2006-01-20 |
Козан Байосайенсиз, Инк. (Us) |
Эпотилон d+фторурацил/гемцитабин
|
|
GB0223380D0
(en)
|
2002-10-09 |
2002-11-13 |
Astrazeneca Ab |
Combination therapy
|
|
EP1552833B1
(en)
*
|
2002-10-16 |
2016-12-28 |
Takeda Pharmaceutical Company Limited |
Process for producing an amorphous optically active isomer of lansoprazole
|
|
JP4749660B2
(ja)
*
|
2002-10-16 |
2011-08-17 |
武田薬品工業株式会社 |
安定な固形製剤
|
|
EP1556356B1
(en)
|
2002-10-21 |
2006-05-31 |
Warner-Lambert Company LLC |
Tetrahydroquinoline derivatives as crth2 antagonists
|
|
EP1566379A4
(en)
|
2002-10-29 |
2005-11-09 |
Kirin Brewery |
CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
|
|
DE10250711A1
(de)
|
2002-10-31 |
2004-05-19 |
Degussa Ag |
Pharmazeutische und kosmetische Zubereitungen
|
|
WO2004041308A1
(en)
|
2002-11-06 |
2004-05-21 |
Cyclacel Limited |
Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
|
|
GB0226434D0
(en)
|
2002-11-13 |
2002-12-18 |
Astrazeneca Ab |
Combination product
|
|
ITSV20020056A1
(it)
|
2002-11-14 |
2004-05-15 |
Alstom Transp Spa |
Dispositivo e metodo di verifica di motori software logici di comando di impianti ferroviari, in particolare di impianti di stazione
|
|
AR042042A1
(es)
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
|
ES2387909T3
(es)
|
2003-01-14 |
2012-10-03 |
Cytokinetics, Inc. |
Compuestos, composiciones y procedimientos de tratamiento de la insuficiencia cardiaca
|
|
JP3581361B1
(ja)
|
2003-02-17 |
2004-10-27 |
株式会社脳機能研究所 |
脳活動測定装置
|
|
ZA200507321B
(en)
|
2003-03-05 |
2007-03-28 |
Celgene Corp |
Diphenylethylene compounds and uses thereof
|
|
EP1604665B1
(en)
|
2003-03-10 |
2011-05-11 |
Eisai R&D Management Co., Ltd. |
C-kit kinase inhibitor
|
|
AU2004220156B2
(en)
|
2003-03-14 |
2007-04-19 |
Taisho Pharmaceutical Co., Ltd. |
Monoclonal antibody and hybridoma producing the same
|
|
RU2366655C2
(ru)
|
2003-03-14 |
2009-09-10 |
Оно Фармасьютикал Ко., Лтд. |
Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
|
|
WO2004087096A1
(en)
|
2003-04-02 |
2004-10-14 |
Pliva-Istrazivanje I Razvoj D.O.O. |
Pharmaceutical compositions having reduced bitter taste
|
|
US20070117842A1
(en)
|
2003-04-22 |
2007-05-24 |
Itaru Arimoto |
Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same
|
|
KR100503949B1
(ko)
|
2003-04-28 |
2005-07-26 |
주식회사유한양행 |
염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
|
|
US7107104B2
(en)
|
2003-05-30 |
2006-09-12 |
Medtronic, Inc. |
Implantable cortical neural lead and method
|
|
JP2005008534A
(ja)
|
2003-06-17 |
2005-01-13 |
Soc De Conseils De Recherches & D'applications Scientifiques (Scras) |
抗癌剤及び癌の治療方法
|
|
US20060167027A1
(en)
|
2003-07-10 |
2006-07-27 |
Wedge Stephen R |
Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
|
|
HUE037508T2
(hu)
|
2003-07-24 |
2018-09-28 |
Glaxosmithkline Llc |
Szájban oldódó filmek
|
|
US20070032521A1
(en)
|
2003-08-15 |
2007-02-08 |
Ab Science |
Use of c-kit inhibitors for treating type II diabetes
|
|
KR20060121818A
(ko)
|
2003-08-21 |
2006-11-29 |
오에스아이 파마슈티컬스, 인코포레이티드 |
Ｎ-치환된 벤즈이미다졸릴 ｃ-ｋｉｔ 억제제
|
|
US7485658B2
(en)
|
2003-08-21 |
2009-02-03 |
Osi Pharmaceuticals, Inc. |
N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
|
|
MXPA06002017A
(es)
|
2003-08-21 |
2006-05-31 |
Osi Pharm Inc |
Pirazolil-amidil-bencimidazolilo n-sustituidos, ibnhibidores de c-kit.
|
|
US7312243B1
(en)
|
2003-08-29 |
2007-12-25 |
Jay Pravda |
Materials and methods for treatment of gastrointestinal disorders
|
|
US20080085902A1
(en)
|
2003-09-23 |
2008-04-10 |
Guido Bold |
Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
|
|
PT2213661E
(pt)
|
2003-09-26 |
2011-12-15 |
Exelixis Inc |
Moduladores de c-met e métodos de uso
|
|
CN101337930B
(zh)
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
|
EP1689376A2
(en)
|
2003-11-28 |
2006-08-16 |
Novartis AG |
Diaryl urea derivatives in the treatment of protein kinase dependent diseases
|
|
US6984403B2
(en)
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
|
MXPA06006406A
(es)
|
2003-12-05 |
2007-03-21 |
Adnexus Therapeutics Inc |
Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2.
|
|
CN101337933B
(zh)
*
|
2003-12-25 |
2011-03-02 |
卫材R&D管理有限公司 |
喹啉羧酰胺的甲磺酸盐的结晶(a)及其制备方法
|
|
EP1713484A2
(en)
|
2004-01-23 |
2006-10-25 |
Amgen Inc. |
Compounds and methods of use
|
|
CN1906166A
(zh)
|
2004-02-27 |
2007-01-31 |
卫材株式会社 |
新型吡啶衍生物及嘧啶衍生物(1)
|
|
KR20050091462A
(ko)
|
2004-03-12 |
2005-09-15 |
한국과학기술연구원 |
푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
|
|
US20050244493A1
(en)
|
2004-04-30 |
2005-11-03 |
Withiam Michael C |
Rapidly disintegrating tablets comprising calcium carbonate
|
|
WO2005113507A1
(en)
|
2004-05-21 |
2005-12-01 |
Novartis Vaccines And Diagnostics Inc. |
Substituted quinoline derivatives as mitotic kinesin inhibitors
|
|
CA2567836A1
(en)
|
2004-06-03 |
2005-12-15 |
F. Hoffmann-La Roche Ag |
Treatment with gemcitabine and an egfr-inhibitor
|
|
US20080214606A1
(en)
|
2004-06-18 |
2008-09-04 |
The Government of the United States of America as represented by The Secretary of the Dept. of ..... |
Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells
|
|
US20050288521A1
(en)
|
2004-06-29 |
2005-12-29 |
Phytogen Life Sciences Inc. |
Semi-synthetic conversion of paclitaxel to docetaxel
|
|
US7306807B2
(en)
|
2004-09-13 |
2007-12-11 |
Wyeth |
Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
|
|
US8772269B2
(en)
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
|
WO2006030947A1
(ja)
|
2004-09-13 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
スルホンアミド含有化合物の血管新生阻害物質との併用
|
|
EP1797881B1
(en)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medicinal composition with improved stability and reduced gelation properties
|
|
JP2008514635A
(ja)
|
2004-09-27 |
2008-05-08 |
コーザン バイオサイエンシス インコーポレイテッド |
特異的キナーゼ阻害剤
|
|
MX2007004247A
(es)
|
2004-10-19 |
2007-06-12 |
Amgen Inc |
Agentes de aglutinacion especifica a angiopoyetina-2.
|
|
WO2007040565A2
(en)
|
2004-11-22 |
2007-04-12 |
King Pharmaceuticals Research & Development, Inc. |
Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
|
|
DE602005017118D1
(de)
|
2004-11-23 |
2009-11-26 |
Dong Wha Pharm Co Ltd |
N-HYDROXY-4-ä5-Ä4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)PHENOXYÜPENTOXYüBENZAMIDIN 2 METHANSULFONSAURESALZ
|
|
CA2589274A1
(en)
|
2004-12-07 |
2006-06-15 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
ZA200705695B
(en)
|
2004-12-21 |
2009-02-25 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
US20060198885A1
(en)
|
2005-02-22 |
2006-09-07 |
Sun Pharmaceutical Industries Ltd. |
Oral pharmaceutical composition
|
|
DE602006021401D1
(de)
|
2005-02-28 |
2011-06-01 |
Eisai R&D Man Co Ltd |
Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
|
|
WO2006090931A1
(ja)
|
2005-02-28 |
2006-08-31 |
Eisai R & D Management Co., Ltd. |
スルホンアミド化合物の抗癌剤との新規併用
|
|
EP2439273B1
(en)
|
2005-05-09 |
2019-02-27 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
WO2007013896A2
(en)
|
2005-05-17 |
2007-02-01 |
Plexxikon, Inc. |
Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
|
|
AU2006248593B2
(en)
|
2005-05-17 |
2011-03-17 |
Actelion Pharmaceuticals Ltd. |
Dispersible bosertan tablet
|
|
MY153898A
(en)
|
2005-06-22 |
2015-04-15 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
US7550483B2
(en)
*
|
2005-06-23 |
2009-06-23 |
Eisai R&D Management Co., Ltd. |
Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
|
|
CA2606719C
(en)
|
2005-06-23 |
2010-08-10 |
Eisai R & D Management Co., Ltd. |
Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same
|
|
JP2008546821A
(ja)
|
2005-06-29 |
2008-12-25 |
ロゼリ、 パトリツィア |
Ｖｅｇｆ受容体を制御する化合物、およびその使用
|
|
EA015535B1
(ru)
|
2005-07-11 |
2011-08-30 |
Никомед Данмарк Апс |
Формуляция бензимидазола
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
US20080219977A1
(en)
|
2005-07-27 |
2008-09-11 |
Isaiah Josh Fidler |
Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
|
|
WO2007015569A1
(ja)
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
|
JP4077028B2
(ja)
|
2005-08-24 |
2008-04-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
新規ピリジン誘導体およびピリミジン誘導体（３）
|
|
AU2006285673B2
(en)
|
2005-09-01 |
2010-12-02 |
Eisai R&D Management Co., Ltd. |
Method for preparation of pharmaceutical composition having improved disintegratability
|
|
KR101353763B1
(ko)
|
2005-11-07 |
2014-01-21 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용
|
|
WO2007061127A1
(ja)
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
多発性骨髄腫に対する抗腫瘍剤
|
|
AR059066A1
(es)
*
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
WO2007097386A1
(ja)
|
2006-02-22 |
2007-08-30 |
Eisai R & D Management Co., Ltd. |
安定化医薬組成物
|
|
AU2007227614B2
(en)
|
2006-03-16 |
2011-01-06 |
Gsk Consumer Healthcare Sarl |
Solid dosage form containing a taste masked active agent
|
|
KR100728926B1
(ko)
|
2006-03-20 |
2007-06-15 |
삼성전자주식회사 |
3축 힌지 구조를 갖는 휴대용 전자기기
|
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
|
EA200970045A1
(ru)
|
2006-06-22 |
2009-06-30 |
Солвей Фармасьютикалс Б.В. |
Фармацевтическая композиция для перорального введения плохо растворимого в воде активного вещества
|
|
AU2007288793B2
(en)
|
2006-08-23 |
2012-04-19 |
Eisai R & D Management Co., Ltd. |
Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
|
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
|
JP2010502209A
(ja)
|
2006-09-07 |
2010-01-28 |
アストラゼネカ アクチボラグ |
Ｒｅｔレセプターチロシンキナーゼを標的とする薬剤による治療のために患者を評価する方法
|
|
RU2462247C2
(ru)
|
2006-10-12 |
2012-09-27 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Способы дозирования перорально активного 1,2,4-оксадиазола для терапии, подавляющей нонсенс-мутацию
|
|
JP2009184925A
(ja)
|
2006-11-02 |
2009-08-20 |
Dai Ichi Seiyaku Co Ltd |
５−（１ｈ−１，２，３−トリアゾール−４−イル）−１ｈ−ピラゾール誘導体
|
|
EP2116246A1
(en)
|
2007-01-19 |
2009-11-11 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of pancreatic cancer
|
|
JP5491199B2
(ja)
|
2007-01-19 |
2014-05-14 |
アルデア バイオサイエンシズ，インコーポレイティド |
Ｍｅｋのインヒビター
|
|
US8962655B2
(en)
|
2007-01-29 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
|
JP2008214249A
(ja)
|
2007-03-02 |
2008-09-18 |
Takeda Chem Ind Ltd |
製剤における溶出改善方法および溶出性の改善された製剤
|
|
KR20090116794A
(ko)
|
2007-03-05 |
2009-11-11 |
교와 핫꼬 기린 가부시키가이샤 |
의약 조성물
|
|
KR20090115866A
(ko)
|
2007-03-05 |
2009-11-09 |
교와 핫꼬 기린 가부시키가이샤 |
의약 조성물
|
|
US7807172B2
(en)
|
2007-06-13 |
2010-10-05 |
University Of Washington |
Methods and compositions for detecting thyroglobulin in a biological sample
|
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
|
EP2175885B1
(en)
|
2007-07-30 |
2016-10-12 |
Ardea Biosciences, Inc. |
Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
|
|
EP2218712B1
(en)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
|
MX2010008187A
(es)
|
2008-01-29 |
2010-08-10 |
Eisai R&D Man Co Ltd |
Uso combinado de inhibidor de angiogenesis y taxano.
|
|
GB2456907A
(en)
|
2008-01-30 |
2009-08-05 |
Astrazeneca Ab |
Method for determining subsequent VEGFR2 inhibitor therapy comprising measuring baseline VEGF level.
|
|
CA2753844A1
(en)
*
|
2008-03-05 |
2009-09-11 |
Vicus Therapeutics, Llc |
Compositions and methods for mucositis and oncology therapies
|
|
US8044240B2
(en)
|
2008-03-06 |
2011-10-25 |
Ardea Biosciences Inc. |
Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
CN102131771A
(zh)
|
2008-04-14 |
2011-07-20 |
阿迪生物科学公司 |
组合物及其制备和使用方法
|
|
JP2009263298A
(ja)
|
2008-04-28 |
2009-11-12 |
Ss Pharmaceut Co Ltd |
不快な味を隠ぺいした経口組成物
|
|
WO2009137649A2
(en)
|
2008-05-07 |
2009-11-12 |
The Trustees Of The University Of Pennsylvania |
Methods for treating thyroid cancer
|
|
EP2288383A1
(en)
|
2008-05-14 |
2011-03-02 |
Amgen, Inc |
Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
|
|
WO2009150256A1
(en)
|
2008-06-13 |
2009-12-17 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Markers for predicting response and survival in anti-egfr treated patients
|
|
KR20110028651A
(ko)
|
2008-07-11 |
2011-03-21 |
노파르티스 아게 |
(ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
|
|
JP5439494B2
(ja)
|
2008-10-21 |
2014-03-12 |
バイエル ヘルスケア エルエルシー |
肝細胞癌と関連するシグネチャ遺伝子の同定
|
|
WO2010086964A1
(ja)
|
2009-01-28 |
2010-08-05 |
株式会社 静岡カフェイン工業所 |
がん治療のための併用療法
|
|
US20120164148A1
(en)
|
2009-08-07 |
2012-06-28 |
The Wistar Institute |
Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer
|
|
CA2771403C
(en)
|
2009-08-19 |
2015-02-24 |
Eisai R&D Management Co. Ltd. |
Quinoline derivative-containing pharmaceutical composition
|
|
CA2771606A1
(en)
|
2009-08-21 |
2011-02-24 |
Mount Sinai School Of Medicine Of New York University |
Methods of using cd44 fusion proteins to treat cancer
|
|
EP2293071A1
(en)
|
2009-09-07 |
2011-03-09 |
Universität Zu Köln |
Biomarker for colorectal cancer
|
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
|
CN103003262A
(zh)
|
2010-07-16 |
2013-03-27 |
协和发酵麒麟株式会社 |
含氮芳香族杂环衍生物
|
|
WO2012010550A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
AU2011281700B2
(en)
|
2010-07-19 |
2017-02-09 |
F. Hoffmann-La Roche Ag |
Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
|
|
JP6055764B2
(ja)
|
2010-07-19 |
2016-12-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
|
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
|
WO2012019300A1
(en)
|
2010-08-10 |
2012-02-16 |
Siu K W Michael |
Endometrial cancer biomarkers and methods of identifying and using same
|
|
WO2012029913A1
(ja)
|
2010-09-01 |
2012-03-08 |
興和株式会社 |
経口剤
|
|
US20120077837A1
(en)
|
2010-09-24 |
2012-03-29 |
Eisai R&D Management Co., Ltd. |
Anti-tumor agent
|
|
BR112013014708B1
(pt)
|
2011-02-28 |
2021-10-19 |
Sunshine Lake Pharma Co., Ltd. |
Composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
|
|
US20120244209A1
(en)
|
2011-03-02 |
2012-09-27 |
Roth Jack A |
Tusc2 therapies
|
|
JP6322413B2
(ja)
|
2011-03-10 |
2018-05-09 |
プロヴェクタス ファーマテック，インク． |
改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ
|
|
SI2691112T1
(en)
|
2011-03-31 |
2018-07-31 |
Merck Sharp & Dohme Corp. |
STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
|
|
MX2013009931A
(es)
|
2011-04-18 |
2013-10-01 |
Eisai R&D Man Co Ltd |
Agentes terapeuticos contra tumores.
|
|
WO2012154935A1
(en)
|
2011-05-12 |
2012-11-15 |
Eisai R&D Management Co., Ltd. |
Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof
|
|
WO2012157672A1
(ja)
|
2011-05-17 |
2012-11-22 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害剤の効果を予測する方法
|
|
EP2714937B1
(en)
|
2011-06-03 |
2018-11-14 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
JP5941558B2
(ja)
|
2012-02-28 |
2016-06-29 |
株式会社ソウル製薬Ｓｅｏｕｌ Ｐｈａｒｍａ． Ｃｏ．， Ｌｔｄ． |
シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
EA037351B8
(ru)
|
2012-05-15 |
2021-04-29 |
Бристол-Майерс Сквибб Компани |
Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
|
|
WO2013171287A1
(en)
|
2012-05-16 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
|
|
PL2904011T3
(pl)
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
|
WO2014087230A1
(en)
|
2012-12-04 |
2014-06-12 |
Eisai R&D Management Co., Ltd. |
Use of eribulin in the treatment of breast cancer
|
|
EP3939614A1
(en)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
KR20230070054A
(ko)
|
2013-03-15 |
2023-05-19 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
|
CN105264380B
(zh)
|
2013-05-14 |
2017-09-05 |
卫材R&D管理有限公司 |
用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
|
|
WO2014208774A1
(en)
|
2013-06-26 |
2014-12-31 |
Eisai R&D Management Co., Ltd. |
Use of eribulin and lenvatinib as combination therapy for treatment of cancer
|
|
US9174998B2
(en)
|
2013-12-25 |
2015-11-03 |
Eisai R&D Management Co., Ltd. |
(6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
KR20160108568A
(ko)
|
2014-02-04 |
2016-09-19 |
인사이트 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합
|
|
JP2017509671A
(ja)
|
2014-03-28 |
2017-04-06 |
ウニベルシタ デリィ ストゥディ ディ ジェノバ |
カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤
|
|
LT3524595T
(lt)
|
2014-08-28 |
2022-09-26 |
Eisai R&D Management Co., Ltd. |
Aukšto grynumo chinolino darinys ir jo gamybos būdas
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
WO2016184436A1
(zh)
|
2015-05-21 |
2016-11-24 |
苏州晶云药物科技有限公司 |
乐伐替尼甲磺酸盐的新晶型及其制备方法
|
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
MX373231B
(es)
|
2015-06-16 |
2020-05-08 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
|
KR102559211B1
(ko)
|
2015-06-23 |
2023-07-25 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
(6S,9aS)-N-벤질-8-({6-[3-(4-에틸피페라진-1-일)아제티딘-1-일]피리딘-2-일}메틸)-6-(2-플루오로-4-하이드록시벤질)-4,7-디옥소-2-(프로프-2-엔-1-일)헥사하이드로-2H-피라지노[2,1-c][1,2,4]트리아진-1(6H)-카복사마이드의 결정
|
|
US20200375975A1
(en)
|
2016-04-15 |
2020-12-03 |
Eisai R&D Management Co., Ltd. |
Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus
|
|
CN107305202B
(zh)
|
2016-04-22 |
2020-04-17 |
北京睿创康泰医药研究院有限公司 |
分析甲磺酸乐伐替尼及其制剂杂质的hplc方法及杂质作参比标准的用途
|
|
JP6581320B2
(ja)
|
2017-02-08 |
2019-09-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
HUE069392T2
(hu)
|
2017-04-04 |
2025-03-28 |
Synthon Bv |
Lenvatinib-mezilátot tartalmazó gyógyszerkészítmény
|
|
WO2018196687A1
(zh)
|
2017-04-25 |
2018-11-01 |
苏州科睿思制药有限公司 |
乐伐替尼甲磺酸盐的新晶型及其制备方法
|
|
CN109988112A
(zh)
|
2017-12-29 |
2019-07-09 |
四川科伦药物研究院有限公司 |
仑伐替尼甲磺酸盐的晶型及其制备方法
|
|
US10583133B2
(en)
|
2018-03-12 |
2020-03-10 |
Shilpa Medicare Limited |
Pharmaceutical compositions of lenvatinib
|
|
WO2019228485A1
(zh)
|
2018-06-01 |
2019-12-05 |
成都苑东生物制药股份有限公司 |
一种甲磺酸乐伐替尼新晶型及其制备方法
|
|
CN110818634B
(zh)
|
2018-08-13 |
2021-11-30 |
上海新礼泰药业有限公司 |
甲磺酸乐伐替尼的精制方法
|
|
CN110903239A
(zh)
|
2018-09-18 |
2020-03-24 |
苏州科睿思制药有限公司 |
乐伐替尼甲磺酸盐的新晶型及其制备方法
|
|
CN110563644A
(zh)
|
2019-10-30 |
2019-12-13 |
北京赛思源生物医药技术有限公司 |
一种仑伐替尼甲磺酸盐的新晶型
|
|
EP4147689A1
(en)
|
2021-09-13 |
2023-03-15 |
Lotus Pharmaceutical Co., Ltd. |
Lenvatinib formulation
|